Trial · NCT02232516
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR), as Defined Per Cheson Criteria | Treatment (Romidepsin, Lenalidomide) | Complete Response (CR) | 6 | participants | |
| Objective Response Rate (ORR), as Defined Per Cheson Criteria | Treatment (Romidepsin, Lenalidomide) | Partial Response (PR) | 9 | participants | |
| Objective Response Rate (ORR), as Defined Per Cheson Criteria | Treatment (Romidepsin, Lenalidomide) | Stable Disease (SD) | 2 | participants | |
| Objective Response Rate (ORR), as Defined Per Cheson Criteria | Treatment (Romidepsin, Lenalidomide) | Progressive Disease (PD) | 6 | participants | |
| Objective Response Rate (ORR), as Defined Per Cheson Criteria | Treatment (Romidepsin, Lenalidomide) | CR + PR | 15 | participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Thrombocytopenia | 10 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Anemia | 8 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Lung Infection | 3 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Sepsis | 3 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Hypoalbuminemia | 7 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Fatigue | 5 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Hyponatremia | 13 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Hypertension | 11 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Hypokalemia | 4 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Hyperglycemia | 4 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Blood Bilirubin Increased | 4 | Participants | |
| Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Romidepsin, Lenalidomide) | Dehydration | 3 | Participants | |
| Progression-free Survival (PFS) | Treatment (Romidepsin, Lenalidomide) | PFS at year 1 | 0.486 | 95% Confidence Interval 0.311 to 0.759 | PFS Probability |
| Progression-free Survival (PFS) | Treatment (Romidepsin, Lenalidomide) | PFS at year 3 | 0.315 | 95% Confidence Interval 0.108 to 0.615 | PFS Probability |
| Overall Survival (OS) | Treatment (Romidepsin, Lenalidomide) | OS at year 1 | 0.711 | 95% Confidence Interval 0.540 to 0.937 | OS Probablilty |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02232516/results